Sri Lanka Renewal Fees and the Five-Year Budget
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Sri Lankan medical device registration certificate is valid for 5 years, and a renewal application must be filed when it expires. The renewal processing fees are: Foreign 750 US dollars; Local – Category A 500 US dollars; Local – Category B 200 US dollars — respectively 75%, 67%, and 80% of the corresponding new application fees. Converted on the April 2026 fee schedule, the rupee totals for the three tiers are 289,655.90, 193,103.93, and 77,241.57 rupees, each inclusive of 18% VAT and 2.5% SSCL. The renewal economics are therefore predictable in advance: a budget can be set for the renewal year at roughly seven to eight tenths of the original application, provided the accumulated changes from the certificate period are handled alongside it rather than left to surface during the renewal itself. The three percentages also make the intent of the fee design visible: the authority charges materially less to continue a review it has already completed once, but it does not waive the cost entirely, so renewal is a budgeted event every certificate cycle rather than a formality.
- Certificate validity is 5 years; renewal must be applied for before expiry.
- Foreign renewal fee: 750 USD, rupee total 289,655.90 (including 18% VAT and 2.5% SSCL).
- Local – Category A: 500 USD, rupee total 193,103.93.
- Local – Category B: 200 USD, rupee total 77,241.57.
- Renewal fees equal 75%, 67%, and 80% of the corresponding new application fees.
- Conversion basis: the April 2026 fee schedule at 319.312 rupees per dollar.
- There is no automatic extension; the certificate lapses on expiry.
2. Legal basis
The renewal fees are published in the NMRA medical device monthly fee schedule. The table below reproduces the three renewal tiers with their converted amounts, VAT, SSCL, and totals as shown for the April 2026 schedule.
| Type | Renewal fee (USD) | Converted (Rs.) | VAT @18% (Rs.) | SSCL 2.5% (Rs.) | Total (Rs.) |
| Foreign | 750 | 239,484.00 | 44,184.80 | 5,987.10 | 289,655.90 |
| Local – Category A | 500 | 159,656.00 | 29,456.53 | 3,991.40 | 193,103.93 |
| Local – Category B | 200 | 63,862.40 | 11,782.61 | 1,596.56 | 77,241.57 |
Data source: NMRA medical device monthly fee schedule (the April 2026 schedule; conversion rate 319.312 rupees per dollar).
As with every rupee figure in this market, the totals above are anchored to the April 2026 schedule and its conversion rate. A renewal falling due in a later month must be recalculated against the schedule in force at that time, since both the rate and the applicable month change on the monthly cycle. The dollar amounts, by contrast, are the stable reference points for long-range planning, which is why the certificate calendar and the budget should both be built in dollars first and converted per month afterwards.
3. Expert insights
Insight one: renewal fees run at 67% to 80% of the new application, not a full re-charge. This shows that Sri Lanka positions renewal as maintaining a status rather than re-reviewing from scratch. For budgeting purposes the renewal year can be estimated at seven to eight tenths of the initial cost. That proportionality is useful for long-range planning: the total cost of keeping a product on the market across two certificate cycles is neither one cycle nor two, but roughly one and three quarters, before any change fees are added.
Insight two: 5 years is a hard deadline with no automatic extension. The certificate ceases to be valid on expiry, and renewal must be initiated before that date. Companies with a portfolio of multiple products should maintain a certificate ledger and schedule each item according to its actual issuance date. A portfolio renewed in batches by product family will have staggered deadlines rather than a single convenient date, so the ledger is what turns an abstract obligation into a dated work plan.
Insight three: renewals are frequently stacked with changes. Over 5 years, the manufacturer’s name, address, and applicable standards may all change, and those changes often need to be resolved before the renewal can proceed. Only by including change fees in the full-cycle budget can the renewal-year overspend be avoided. The practical reading is that the renewal year is the most expensive year of the cycle for a reason: it absorbs both the renewal fee itself and the backlog of changes that accumulated quietly since issuance. Treating the renewal year as a separate budget line, rather than spreading its cost evenly across the cycle, is what keeps the portfolio plan honest when the calendar reaches month sixty.
4. Practical recommendations
- GRZAN maintains a certificate calendar for each client: a horizontal axis of 60 months with one bar per certificate, marking the issuance date, the renewal initiation date, and the expiry date.
- Before each renewal, run a review of the change ledger and clear the changes accumulated over the 5 years in one pass, saving a separate round of change procedures.
- Schedule the renewal initiation date comfortably before expiry, since the certificate lapses on expiry with no automatic extension.
- Set the renewal budget at seven to eight tenths of the new application cost, using the current monthly fee schedule for conversion.
- Include accumulated change fees in the full-cycle budget so the renewal year does not exceed it unexpectedly.
- Confirm that the yellow receipt is obtained after payment, completing the renewal payment record.
5. Verification checklist
- □ A certificate ledger has been established (issuance date / expiry date)
- □ The renewal fee has been checked against the current monthly fee schedule
- □ The renewal initiation time has been scheduled (before expiry)
- □ Changes accumulated over the 5-year period have been reviewed
- □ Change fees have been included in the full-cycle budget
- □ It has been confirmed that the yellow receipt is obtained after payment
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Regulatory information verified as of 28 October 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us